NCT01575873COMPLETEDanonymous

A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Indication / condition

AI-normalized

Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Intervention

Source record

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Source & freshness

Source record

NCT ID

NCT01575873

Original source

ClinicalTrials.gov

Source last updated

Jul 27, 2018

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01575873

Title

A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Condition normalized

Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Target normalized

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Interventions

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Public preview

Source record

This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01575873

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 27, 2018

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01575873

Indication

Steroid-induced Osteopor, Glucocorticoid-induced Ostepor

Modality

monoclonal antibody

Target

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Intervention

Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.